EMPOWERING STAKEHOLDERS IN DRUG POLICY MAKING BY RESEARCH EVIDENCE TO IMPROVE REGULATIONS FOR ETHICAL DRUG ADVERTISEMENT TOWARD RATIONAL DRUG USE Pham.

Slides:



Advertisements
Similar presentations
A study of advertisements in five African countries
Advertisements

Sub-regional Training Workshop on
WTO - TBT Committee Ana Maria Vallina, PhD Coordination Among Regulatory Bodies: The Chilean Experience Ana Maria Vallina PhD Head of Foreign Trade Department.
Project Advisory Committee Meeting 26th June 2012, New Delhi Vikash Batham CUTS International Exploring the Interplay between Business Regulation and Corporate.
History of Nuclear Safety Legislation in Pakistan
Country Ownership Strategies: Asia Pacific Leadership Forum on Health Information Systems WHO WPRO Conference Center June, 2011.
ARQ part II data management Training pack 2: Monitoring drug abuse for policy and practice.
Company LOGO ON Primary Teacher Professional Profiles REPORT MINISTRY OF EDUCATION AND TRAINING PRIMARY TEACHER DEVELOPMENT PROJECT June 2006 A Prof. Nguyen.
Kampala, Uganda, 23 June 2014 E-Waste Management in Uganda Michael Ocero, Acting Commissioner – IT Dept. Ministry of ICT ITU Regional.
E-Waste Management Policy and Strategy in Uganda
Yangon, The Republic of the Union of Myanmar, November 2013 ICT standardization framework in Viet Nam and participation in ITU Nguyen Thi Khanh Thuan,
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
MeTA Jordan Executive Summary Baseline data is an important source for policy makers to diagnose the pharmaceutical and health sector situation in order.
BY Margaret Kakande President, Uganda Evaluation Association 1.
Dr. Danister L. Perera Registrar Ayurvedic Medical Council Sri Lanka
Dorcas Sithole Mental Health Department Ministry of Health & Child Welfare 1.
Ministry of Education and Youth Republic of Moldova 1 Implementing the Bologna Process in the Republic of Moldova: Achievements and Problems Viorelia Moldovan-Batrinac,
Identify the institutions which have a stake in the
Kingdom of Morocco High Commision for Planning Directorate of Statistics 1 International Association for Official Statistics IAOS 2014 STATISTICS OF TRANSPORT.
Japan Medical Device Market Overview Ian Clements Office of Japan U.S. Department of Commerce April 10, 2008.
MONRE UNEP-RISO NATIONAL WORKSHOP ON CAPACITY DEVELOPMENT FOR CDM Hanoi, 27-28/11/2002 Proposal for establishing National Authority on CDM in Vietnam Dr.
INTRODUCTION TO RA.
CHAPTER 5 DRUGS, BIOLOGICALS, MEDICAL EQUIPMENT AND INFRASTRUCTURE Ts. Nguyễn Thị Kim Chúc.
March 2015 Inter-American Network for the Prevention of Violence and Crime.
Proposed plan to implement Capacity Development for CDM project in the forthcoming period Dr. DAO DUC TUAN Eng. NGUYEN KHAC HIEU National Office for Climate.
Margarit MELIKYAN Drug Utilization Research Group PO, Armenia, National Institute of Health Access to and Use of Medicines by Households in Armenia: Impact.
Collusion among Health Service Providers in India Need for Regulatory Enforcement PRESENTATION ON BACKGROUND AND DRAFT PROJECT METHODOLOGY.
QUALITY OF DRUG ADVERTISEMENTS FOLLOWING THE DEREGULATION OF MASS MEDIA IN INDONESIA Sri Hidayati, Siti Munawaroh, Sulanto Saleh-Danu International Network.
Building Consensus while assessing the needs and preparing the National Development Strategy for in order to ensure universal primary education.
Copyright © 2014 by The University of Kansas Health Impact Assessment.
Prasetyadi Utomo Ministry of Environment of Indonesia CD4CDM Workshop Pathumthani, Thailand 19 – 21 October, 2005 Indonesia’s Policy on CDM Implementation.
Dr. Nguyen Dinh Cung President, Central Institute for Economic Management.
ROMANIA MINISTRY OF HEALTH GENERAL DIRECTORATE OF PUBLIC HEALTH Health Promotion Unit Cristina Padeanu, MSc.
Policy track summary ICIUM 2011 – 18 Nov Policy track topics 1.The pharmaceutical policy process 2.Quality and safety of medicines in LMIC 3.Policy.
Group 3 1) Nguyen Huu Quy 2) Hoang Tran Duc Hong 3) Nguyen Ngoc Tuyet Mai 4) Ho Thai Binh 5) Dang Van Dao.
SOUTH AFRICA’S PARTICIPATION AT THE 6 TH SESSION OF THE WORLD URBAN FORUM Presentation to the Human Settlements Portfolio Committee 15 August 2012.
Promoting Drug and Therapeutics Committees in the Developing World
What are coalitions? A coalition is a formal arrangement for cooperation and collaboration between groups or sectors of the community, in which each group.
THE PRESIDENCY African Youth Charter January, 2009.
SEVERAL ISSUES OF CAPACITY BUILDING FOR CDM IN RESEARCH AGENCIES AND UNIVERSITIES Mr. Nguyen Mong Cuong Institute of Meteorological and Hydrology Mr. Bui.
DETERMINE Working document # 4 'Economic arguments for addressing social determinants of health inequalities' December 2009 Owen Metcalfe & Teresa Lavin.
WHO-Technical Briefing Seminar | October-November 2012 Dr Cécile Macé 1 |1 | Good Governance for Medicines Programme Dr Cécile Macé EMP/MPC.
An Intervention To Improve Antibiotic Prescribing Habits of Doctors in a Teaching Hospital Ofei F, Forson A, Tetteh R, Ofori-Adjei D University of Ghana.
Department of Labour Presentation of ILO 93 rd Conference to the Portfolio Committee on Labour 8 November 2005.
A FORMATIVE STUDY TO DESIGN AN INTERVENTION INVOLVING MOTHERS, DRUGS VENDORS AND HEALTH WORKERS IN A SELF-PROCESS OF BEHAVIORAL CHANGE FOR RATIONAL DRUG.
Manager Ethics European social dialogue Slovak University of Technology Faculty of Material Science and Technology in Trnava.
Trade & Access to Medicines in India Centre for Trade & Development
Ministry of Trade and Industry A tool for regulatory transparency Case: Balanced gender representation on company boards Regional Capacity-Building Seminar.
National Research and Development Centre for Welfare and Health Knowledge for welfare and healthKyiv March 22, Round Table on Discussion of the Project.
CDA: May CENTRAL DRUG AUTHORITY MANDATE A PRESENTATION TO THE PARLIAMENTARY PORTFOLIO COMMITTEE ON SOCIAL DEVELOPMENT PART 2.
Capacity-Building Needs of Ghana By Harrison Dapaah and Alex Ablordey Presented at the Dissemination Workshop of ECIATA-EDULINK II Project at Meaglant.
24/11/2009| Prison health reforms - the situation in Norway | 1 Prison Health Reforms in Norway - The “Import Model” Dr. Jon Hilmar Iversen Head of Division.
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 28 – Consumer and Health Protection.
2.4 Public Policy How do the federal and provincial governments make public policy?
April Amman, Jordan DoHoon KIM Senior Research Fellow Korea Institute for Industrial Economics and Trade.
Prescription Drug Advertising
ROLES AND RESPONSIBILITIES OF TFDA ON ADDO PROGRAM
Dr Prak Piseth Raingsey Director Department of Preventive Medicine
National Anti-Trafficking Coordination Mechanism in Latvia
October 2012 Brussels, Belgium
ABSTRACT Problem statement: The Lao PDR National Drug Policy (NDP) Program, implemented by the Ministry of Health supported by the Swedish International.
Addressing violence against women in the Americas: the role of health systems Special Meeting of The Permanent Council On The Subject “Addressing Violence.
USING A POSTER COMPETITION TO PROMOTE RATIONAL DRUG USE
Prof. Lalko Dulevski President of the ESC of Bulgaria
Prof. Lalko Dulevski President of the ESC of Bulgaria
ICT standardization framework in Viet Nam and participation in ITU
PH Dung, NTK Chuc and Dennis Ross Degan
Funding by ARCH (Boston University)
Presentation transcript:

EMPOWERING STAKEHOLDERS IN DRUG POLICY MAKING BY RESEARCH EVIDENCE TO IMPROVE REGULATIONS FOR ETHICAL DRUG ADVERTISEMENT TOWARD RATIONAL DRUG USE Pham Huy Dung and Nguyen Thi Kim Chuc Institute for Health Environment and Development

Problem Statement: Consequences of the socio-economic reform and the health sector reform in Vietnam:  Drugs become more available -> no more shortage of drugs  Too many drugs -> foreign and local companies compete for drug sell -> increasing public spending on drugs and making drug advertisement unethical, which could have negative impact on rational drug use.

Objectives  Collect information on drug advertisement  Inform stakeholders in drug policy making about research evidence on unethical drug advertisement for them to improve regulations for drug promotion toward rational drug use  Evaluate change in drug advertisement  Propose new intervention (regulation)

Design,Setting and Population Design: Pre post evaluation of the regulatory status and its impact on advertisements to the public, on advertisements to doctors as well as on promotional practice. Setting and Population: Various stakeholders in drug policy making: the Committee for social affairs of the National Assemble, the Prime Minister Research Commission, the Committee of Science and Education of the Leading Party (the Communist Party), various departments of the Ministry of Health, various non-government association (the Youth Federation, the Women Union, etc.)

Intervention  Research results from a study on country status, regulatory status, drug advertisements to the public, advertisements to doctors and promotional practice in 1998 were used to inform stakeholders in drug policy making about evidence of unethical aspects in drug promotion harmful to rational drug use  The information process has been implemented through meetings, seminars and workshops using the Meta analysis method

Results: Improvement of the Regulatory Status  Ordinance of the national Assemble 39/2001/PL for advertisement  Ordinance of the President November 30,2001 for advertisement  Decree of the Government 59/2002 for advertisement  Decree of the Ministry of Health 2557/2002/QD-BYT for drug advertisements  Decree of the Ministry of Health on the list of drugs that are allowed for advertisement on March 12, 2003

Results: Advertisements and Promotional Practice  Advertisements  Advertisement to the general public: no improvement in generic names and contra- indications, some improvement in FDA approval (0%->22% in radios and TVs; 0%->47% in magazines)  Advertisement to doctors: no improvement in generic names, some improvement in contra- indications (5.6%->55.6%) and in FDA approval (0%-> 34.6%)  Promotional Practice  Improvement in knowledge among doctors, medical representatives and manufacturers

Discussion and Conclusions  Drug advertisement should respond to requirement of drug information  Rapid effect for improvement of the regulatory status  Low effect of the regulatory status on practice  Enforcement of regulations could control some issues such as generic name, contra- indications, FDA approval, etc.  How to control medical representatives?